Advisory Research Inc Prothena Corp Public LTD CO Transaction History

Advisory Research Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$48.26 - $78.59 $718,494 - $1.17 Million	14,888 Added 208.19%	22,039 $1.5 Million
Q1 2023 May 12, 2023	BUY	$46.97 - $58.27 $1,456 - $1,806	31 Added 0.44%	7,151 $346,000
Q4 2022 Feb 13, 2023	BUY	$52.05 - $65.0 $370,596 - $462,800	7,120 New	7,120 $428,000
Q1 2022 May 16, 2022	SELL	$30.27 - $49.22 $332,213 - $540,189	-10,975 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$42.11 - $73.26 $366,735 - $638,021	-8,709 Reduced 44.24%	10,975 $542,000
Q3 2021 Nov 12, 2021	BUY	$48.2 - $78.89 $948,768 - $1.55 Million	19,684 New	19,684 $1.4 Million

198

44.5M

601K

259K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $701M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Advisory Research Inc, based on Form 13F filings with the SEC.

Stay updated on Advisory Research Inc with notifications on news.